This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
ContinueWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
LinkGevity Awarded Innovate UK Smart Grant for Anti-Necrotic TM Research to Prevent Kidney Deterioration
Read full release
Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
Read full release
Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
Read full release
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens
Read full release
AlgoTx Announces Results of its Phase 2 “ACT” Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
Read full release
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
Read full release
Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials
Read full release
LinkGevity Announces Investment from the KQ Labs Programme Delivered by the Francis Crick Institute — First-in-Class Anti-Necrotic Therapeutic set to initiate clinical trials for kidney disease and accelerated aging in 2025
Read full release
AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure – Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF)
Read full release
MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia – EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorder
Read full release
MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director
Read full release
Epitopea and Genevant Sciences Announce Collaboration Agreement
Read full release
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
Read full release
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer
Read full release
ExeVir Announces Michael Garrett as New Chief Executive Officer
Read full release
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Read full release
BC Platforms, Modirum Platforms, VEIL.AI and Productivity Leap Publish Reference Architecture for Real-World Data Optimized European Health Data Space Secondary Framework (EHDS2) Implementation
Read full release
BC Platforms’ European Health Data Space-Ready Platform to Support EU’s Digital Healthcare Transformation
Read full release
Epitopea Closes USD $31 million Pre-Series A Financing
Read full release
Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013 datam at ID Week 2024
Read full release
MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity
Read full release
MONCYTE Health Raises EUR 1 Million Seed Capital to Advance Personalized Treatment for High Cholesterol
Read full release
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
Read full release
MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme
Read full release
CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Platform Enabling the Development of RNA-based Immunotherapies
Read full release
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
Read full release
LinkGevity Awarded Deep-Tech Grant from Horizon Europe
Read full release
Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme
Read full release
LinkGevity Secures Place in Prestigious SPACE-H Accelerator Program
Read full release
TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
Read full release
Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer
Read full release
BC Platforms Announces Appointment of New Chairperson Dr. Jan Berger, Seasoned Executive and Strategist, to Drive Strategic Agenda
Read full release
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Read full release
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Read full release
CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
Read full release
Epitopea Announces Leadership Transition and New Appointments
Read full release
Pan Cancer T secures eur 4.25 Million in Seed Extension Round to advance next-generation T cell therapies
Read full release
Concr launches trial using digital twins for outcome prediction in breast cancer
Read full release
Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studiess
Read full release
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata
Read full release
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
Read full release
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
Read full release
Anocca Appoints Christiane Hanke-Harloff to Board of Directors
Read full release
Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
Read full release
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
Read full release
Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications
Read full release
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
Read full release
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
Read full release
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
Read full release
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)
Read full release
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
Read full release
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Read full release
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
Read full release
Anocca Appoints Martin Welschof to Board of Directors
Read full release
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
Read full release
EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO
Read full release
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Read full release
Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
Read full release
CV6 Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial
Read full release
GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis
Read full release
SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata
Read full release
MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
Read full release
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
Read full release
BC Platforms Acquires Medexprim, Paving the Way for Global Leadership in Real-World Data and Real-World Evidence Analytics
Read full release
Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma
Read full release
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
Read full release
GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100
Read full release
BC Platforms Partners with NTT to Accelerate Data-Driven Medicine in Japan
Read full release
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
Read full release
Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology
Read full release
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
Read full release
BC Platforms Appoints Mikaela Bruhammar as Chief Operating Officer, Markets
Read full release
AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia
Read full release
BC Platforms Appoints Dr. Ben Illigens as Chief Medical Officer
Read full release
ExeVir Bio Appoints a Chief Scientific Officer
Read full release
GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development
Read full release
LEX Diagnostics Appoints Chief Technology Officer
Read full release
EnteroBiotix appoints Elmar Schnee as Executive Chairman
Read full release
BC Platforms Advances BC|RQUEST to Revolutionize Drug Discovery and Development
Read full release
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
Read full release
IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders
Read full release
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Read full release
GPCR passes Technology Evaluation process for listing on KOSDAQ
Read full release
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc. Rahway NJ USA
Read full release
Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study
Read full release
BC Platforms Expands Data Partner Network with Major Brazilian Cardiovascular Health Institution
Read full release
Needle-free vaccine delivery platform aims to end frozen storage needs and improve access
Read full release
VaxEquity and CPI Announce Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics
Read full release
Anocca raises SEK 400 million for large-scale development of cancer cell therapies
Read full release
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
Read full release
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 – Innovative Immuno-oncology
Read full release
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
Read full release
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
Read full release
Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders
Read full release
SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
Read full release
IRBM Selected for Participation in National Chemical Biology Consortium
Read full release
aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress
Read full release
BC Platforms appoints Dr Carolin Bender as Chief Medical Officer
Read full release
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
Read full release
GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy
Read full release
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
Read full release
MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director.
Read full release
Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Read full release
Primobolan for Sale in the USA, AU, and UK: Top Brands You Must Know
Athletes and bodybuilders worldwide, from the US to Australia and the UK, have long sought enhancements that can propel their performance to the next level. With the rise of Primobolan for sale, access to a highly sought-after anabolic steroid has never been more within reach. Learn about the benefits that Primobolan brings to the table, […]
Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
Read full release
LEX Diagnostics Appoints Scott O’Brien as LEX Board Member
Read full release
Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
Read full release
Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology
Read full release
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
Read full release
GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma
Read full release
LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer
Read full release
Valo Therapeutics selects Exothera to develop large scale oncolytic Adenovirus manufacturing
Read full release
ExeVir Bio secures EUR 25 million venture debt financing from European Investment Bank
Read full release
BC Platforms Selected as Partner to deliver key Singapore Population Health Study
Read full release
Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer
Read full release
Etcembly Announces Breakthrough in Optimising TCR Assets
Read full release
Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint
Read full release
Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals
Read full release
BC Platforms Partners with EU Funded, AI-Driven Cancer Data Initiative
Read full release
EnteroBiotix partners with Imperial College London to advance microbiome therapeutics
Read full release
BC Platforms Announces Powerful Patient Data Sharing Platform to speed up Biotech R&D Process
Read full release
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US Helsinki, Finland
Read full release
BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
Read full release
BC Platforms Announces Partnership With CENTOGENE to Enable Access to Data-Driven Insights
Read full release
CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
Read full release
AdAlta and GPCR Therapeutics collaborate on novel cancer therapeutics
Read full release
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
Read full release
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
Read full release
EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics
Read full release
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
Read full release
SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
Read full release
GPCR Therapeutics Expands US Facilities with Relocation to Redwood City
Read full release
Valo Therapeutics Announces Scientific Advisory Board
Read full release
Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies
Read full release
Orthox Announces MHRA Authorisation for Clinical Trial of Knee Cartilage Repair FibroFix™ Product Platform
Read full release
EnteroBiotix Appoints David Lawrence to its Board of Directors
Read full release
Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board
Read full release
Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
Read full release
TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets
Read full release
Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.
Read full release
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Read full release
BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia
Read full release
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Read full release
BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals
Read full release
BC Platforms Announces Partnerships with Three Finnish Biobanks to Advance Novel Diagnostics and Treatments
Read full release
GPCR Therapeutics Expands Scientific Advisory Board
Read full release
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Read full release
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases
Read full release
EIB provides €15 million to fund coronavirus research at IRBM
Read full release
Renowned Immunotherapy Expert Dr. Michael Kalos Joins Anocca’s Scientific Advisory Board
Read full release
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
Read full release
Oppilotech and Evariste Technologies Announce Partnership to Develop First-in-Class Antibacterial Programme
Read full release
Etcembly Appoints Scott Cuthill as Chief Business Officer
Read full release
BC Platforms Adds Japan’s Mitsubishi Space Software to its Global Data Network
Read full release
Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platform
Read full release
SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor
Read full release
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
Read full release
Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
Read full release
Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China
Read full release
BC Platforms Delivers on Global Real-World Data and Platform Access
Read full release
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
Read full release
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
Read full release
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Read full release
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
Read full release
Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO
Read full release
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
Read full release
Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
Read full release
Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development
Read full release
SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies
Read full release
Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
Read full release
Amphista Therapeutics Appoints CBO, Beverley Carr
Read full release
EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline
Read full release
BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia
Read full release
Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
Read full release
VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform
Read full release
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Read full release
BC Platforms to Enable Longitudinal RWD and Genomics Access for Drug Development in Africa
Read full release
Anocca appoints Jacob Michlewicz as CFO
Read full release
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
Read full release
Vaccitech to join Brookfield’s Harwell Campus
Read full release
Vaccitech Oncology Limited’s ChAdOx1/MVA prime-boost immunotherapeutic shows preclinical potential as a novel cancer treatment
Read full release
BC Platforms Launches packaged end-to-end solution for NGS laboratories with Sentieon to accelerate adoption of NGS testing
Read full release
TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
Read full release
Anocca raises $47m in a Series B Financing to advance its industrialised approach to TCR-T cellular immunotherapy
Read full release
Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
Read full release
Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
Read full release
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
Read full release
Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
Read full release
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
Read full release
Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
Read full release
BC Platforms Announces CureDuchenne Collaboration to Promote Critical Research & Accelerate Drug Development
Read full release
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
Read full release
New BC Platforms Partnership with Artisan Biomed to Unlock African Access to Precision Medicine
Read full release
Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
Read full release
Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug
Read full release
Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
Read full release
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
Read full release
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial
Read full release
Vaccitech Announces Pricing of Initial Public Offering
Read full release
BC Platforms Partnership to Drive New UK Health Data Research Tool
Read full release
BC Platforms Partners with TripleBlind to Power Federated Artificial Intelligence (AI) Data Privacy Approaches
Read full release
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Read full release
BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes
Read full release
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
Read full release
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
Read full release
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
Read full release
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Read full release
TILT Biotherapeutics advances cancer immunotherapy clinical trial achieving primary end point in the first cohort
Read full release
Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine
Read full release
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
Read full release
BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research
Read full release
Advent Life Sciences Announces Close of Two New Funds Totalling $215 million
Read full release
Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline
Read full release
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
Read full release
X-Bolt Features in Largest Ever Hip Fracture Fixation Trial Publication
Read full release
BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19
Read full release
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
Read full release
InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19
Read full release
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
Read full release
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
Read full release
BC Platforms delivers data platform for UK research consortium to improve detection of lung cancer
Read full release
BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform
Read full release
Oxford University breakthrough on global COVID-19 vaccine
Read full release
BC Platforms Announces Partnership with CO-CONNECT Consortium to accelerate COVID-19 research
Read full release
Vaccitech expands management team with hires including CMO and CFO
Read full release
BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research
Read full release
Theolytics Announces Appointment of Immatics’ Carsten Reinhardt to its Board of Directors
Read full release
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
Read full release
Valo Therapeutics Appoints Industry Veteran Paul Higham as CEO
Read full release
IRBM to collaborate with MSD to develop peptides against coronavirus
Read full release
Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
Read full release
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Read full release
TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic
Read full release
Valo Therapeutics Announces Board Appointment of Dr Mai-Britt Zocca
Read full release
IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
Read full release
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
Read full release
Amphista Therapeutics appoints Ian Churcher as CSO
Read full release
BC Platforms and Kaiser Permanente Win 2020 Microsoft Health Innovation Award for Precision Medicine Collaboration
Read full release
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
Read full release
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Read full release
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Read full release
Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine
Read full release
Oxford COVID-19 vaccine begins human trial stage
Read full release
Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
Read full release
Amphista Therapeutics raises $7.5m Series A round
Read full release
World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research
Read full release
Vaccitech to Present at Solebury Trout Virtual Investor Conference
Read full release
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Read full release
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Read full release
BC Platforms Appoints Board Member Karen Tay Koh to Accelerate Asia Growth
Read full release
FinnGen Grows to One of the Largest Private-Public Studies in the World
Read full release
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
Read full release
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Read full release
Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
Read full release
Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
Read full release
BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers
Read full release
BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics
Read full release
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Read full release
IRBM signs agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies.
Read full release
CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
Read full release